| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
77,367 |
66,769 |
$15.66M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
39,515 |
31,956 |
$8.28M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
21,995 |
17,808 |
$662K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
1,614 |
1,115 |
$570K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,307 |
3,803 |
$499K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
908 |
614 |
$413K |
| G0378 |
Hospital observation service, per hour |
581 |
410 |
$214K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,784 |
9,657 |
$165K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
767 |
588 |
$158K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,968 |
2,770 |
$45K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,282 |
4,212 |
$31K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
506 |
447 |
$21K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
664 |
587 |
$16K |
| 80053 |
Comprehensive metabolic panel |
30,897 |
25,011 |
$14K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,479 |
6,706 |
$14K |
| 43248 |
|
36 |
24 |
$13K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
359 |
314 |
$13K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
278 |
249 |
$8K |
| 87430 |
|
3,045 |
2,862 |
$7K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
79 |
70 |
$7K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
14,245 |
11,033 |
$6K |
| 84484 |
|
9,943 |
7,087 |
$5K |
| 85027 |
|
45,129 |
35,716 |
$5K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
8,368 |
6,509 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
53 |
25 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
12,300 |
9,539 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
1,492 |
1,249 |
$3K |
| 81001 |
|
18,548 |
15,819 |
$2K |
| 84703 |
|
10,810 |
9,945 |
$2K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,579 |
1,337 |
$1K |
| 83655 |
|
29 |
29 |
$988.81 |
| 70450 |
Computed tomography, head or brain; without contrast material |
271 |
199 |
$839.10 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
236 |
184 |
$683.54 |
| 83690 |
|
6,352 |
5,268 |
$671.16 |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
17 |
13 |
$640.44 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
7,429 |
6,572 |
$626.83 |
| 87070 |
|
326 |
310 |
$359.99 |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
205 |
163 |
$327.47 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,253 |
3,864 |
$300.67 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,392 |
1,258 |
$240.00 |
| 83735 |
|
1,461 |
1,006 |
$227.24 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,104 |
895 |
$217.87 |
| 85018 |
|
28 |
28 |
$200.08 |
| 36415 |
Collection of venous blood by venipuncture |
303 |
197 |
$145.72 |
| 85610 |
|
1,638 |
1,253 |
$91.55 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
918 |
766 |
$86.42 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
31 |
24 |
$65.20 |
| 85730 |
|
920 |
700 |
$57.36 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
168 |
154 |
$52.20 |
| 86710 |
|
338 |
293 |
$47.44 |
| 83880 |
|
139 |
101 |
$37.07 |
| 81003 |
|
4,325 |
3,537 |
$34.90 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,966 |
1,599 |
$27.39 |
| 86756 |
|
41 |
39 |
$25.07 |
| 87040 |
|
295 |
176 |
$20.22 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
370 |
336 |
$14.91 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,164 |
766 |
$13.00 |
| 80047 |
|
88 |
81 |
$12.80 |
| 85379 |
|
66 |
49 |
$11.23 |
| 83605 |
|
465 |
372 |
$11.21 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
562 |
507 |
$7.64 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,720 |
2,470 |
$4.10 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
652 |
586 |
$0.00 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
274 |
229 |
$0.00 |
| 85049 |
|
32 |
25 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
24 |
24 |
$0.00 |
| 82248 |
|
34 |
26 |
$0.00 |
| 73630 |
|
12 |
12 |
$0.00 |
| 80061 |
Lipid panel |
15 |
12 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
41 |
37 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
15 |
13 |
$0.00 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
128 |
108 |
$0.00 |
| 88342 |
|
603 |
399 |
$0.00 |
| 82784 |
|
52 |
45 |
$0.00 |
| A9270 |
Non-covered item or service |
65 |
41 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
24 |
13 |
$0.00 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
32 |
24 |
$0.00 |
| J3490 |
Unclassified drugs |
13 |
12 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
13 |
13 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
29 |
27 |
$0.00 |